Craniopharyngioma medical therapy

Revision as of 21:15, 23 August 2015 by Sujit Routray (talk | contribs)
Jump to navigation Jump to search

Craniopharyngioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Craniopharyngioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Craniopharyngioma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Craniopharyngioma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Craniopharyngioma medical therapy

CDC on Craniopharyngioma medical therapy

Craniopharyngioma medical therapy in the news

Blogs on Craniopharyngioma medical therapy

Directions to Hospitals Treating Craniopharyngioma

Risk calculators and risk factors for Craniopharyngioma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

Patients with craniopharyngioma have many treatment options. The selection depends on the size, location of the tumor. The options are surgery, radiation therapy, chemotherapy, or a combination of these methods.

Medical Therapy

  • Although the mainstay of therapy for craniopharyngioma is surgery with or without radiation, there are certain indications for medical therapy as well, mostly in treating recurrent tumors.
  • Although systemic therapy is generally not utilized, it has been shown that the use of subcutaneous pegylated interferon alpha-2b to manage cystic recurrences can result in durable responses.[1]
  • The chemotherapy drugs Paclitaxel and Carboplatin have shown a clinical (but not statistical) significance in increasing the survival rate in patients who've had gross total resections of their malignant tumors.
  • Cystic recurrences may be treated with intracavitary instillation of varying agents via stereotactic delivery or placement of an Ommaya catheter. These agents have included radioactive P-32 or other radioactive compounds, bleomycin or interferon-alpha. These strategies have been found to be useful in certain cases, and a low risk of complications has been reported. However, none of these approaches have shown efficacy against solid portions of the tumor.[2]
  • The following is an example of a national and/or institutional phase II clinical trial that is currently being conducted. PBTC-039 (NCT01964300) (Peginterferon Alpha-2b) in treating younger patients with craniopharyngioma that is recurrent or cannot be removed by surgery.[3]

References


Template:WikiDoc Sources